Centocor, Inc.

New York University

Alza Corporation

Other

Emergex USA Corporation

Zosano Pharma Corporation

Zp Opco, Inc.

Peter E. Daddona

Junming Le

David M. Knight

John Ghrayeb

Jan Vilcek

Scott A. Siegel

Peter E Daddona

David M Knight

Jan T Vilcek

Scott A Siegel

Michel J N Cormier

Mahmoud Ameri

Yi Ao

Joseph Creagan Trautman

Yuh-Fun Maa

James Matriano

Donald Kellerman

Richard L Keenan

Wendy A Young

Marika Kamberi

Juanita A Johnson

WeiQi Lin

Ahmad P Samiee

Michel J Cormier

Wei-Qi Lin

Kofi Nyam

Ronald P Haak

Rodger P McEver

Patrick S-l Wong

Koon Y Pak

Avtar S Nat

Hyunok Lynn Kim

Harvey J Berger

Michael G Zuck

Mark Nedelman

Michael J Cormier

James A Matriano

Wei Qi Lin

John Ghraveb

Jumming Le

Peter C Schmidt

Marika Kamberl

Gregory T Fieldson

Michel JN Cormier

Compositions, devices and methods employing therapeutic concentrations of a triptan for treatment of migraine are described. Also described are methods and apparatuses for delivery of zolmitriptan for achieving a Tas quick as 2 minutes and not later than 30 minutes in the majority of subjects.

Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines

Compositions, devices and methods employing therapeutic concentrations of a triptan for treatment of migraine are described. Also described are methods for treating migraine by administering zolmitriptan using an adhesive dermally-applied microarray (ADAM) resulting in rapid and durable pain relief, pain freedom and reduction in most bothersome migraine-associated symptoms (MBS), or a combination thereof.

Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches

There is provided glucagon formulations suitable for preparing coatings on microneedle patches for the transdermal delivery of glucagon. The coated patches may be used for the treatment of low blood sugar in diabetic patients. Also provided are glucagon loaded patches, methods for their preparation, and methods of their use.

Stable glucagon peptide formulations

An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member.

Apparatus and method for transdermal delivery of parathyroid hormone agents

A device () and method are provided for percutaneous transdermal delivery of a potent pharmacologically active agent. The agent is dissolved in water to form an aqueous coating solution having an appropriate viscosity for coating extremely tiny skin piercing elements (). The coating solution is applied to the skin piercing elements () using known coating techniques and then dried. The device () is applied to the skin of a living animal (e.g., a human), causing the microprotrusions () to pierce the stratum corneum and deliver a therapeutically effect dose of the agent to the animal.

Transdermal drug delivery devices having coated microprotrusions

Apparatus for transdermal delivery of parathyroid hormone agents

The device including a plurality of stratum corneum-piercing microprojections, and a solid coating disposed upon the microprojections, wherein the solid coating includes at least one beneficial agent and a biocompatible carrier is provided. The device is applied to the skin of a living animal (e.g., a human), causing the microprojections to pierce the stratum corneum and deliver an effective dose of the agent to the animal.

Microprojection array having a beneficial agent containing coating

A method and device are described for applying a microprotrusion member () including a plurality of microprotrusions () to the stratum corneum with impact. The method and device are used to improve transport of an agent across the skin for agent delivery or sampling. The applicator () causes the microprotrusion member () to impact the stratum corneum with a certain amount of impact determined to effectively pierce the skin with the microprotrusions (). The preferred applicator () impacts the stratum corneum with the microprotrusion member () with an impact of at least 0.05 joules per cmof the microprotrusion member () in 10 msec or less.

Apparatus and method for piercing skin with microprotrusions

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&#x3b1; (TNF&#x3b1;) and are useful in vivo diagnosis and therapy of a number of TNF&#x3b1;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

Methods of treating vascular inflammatory pathology using anti-TNF antibodies and fragments thereof

Growing community of inventors

Menlo Park, CA, United States of America

Peter E Daddona